

October 16, 2017



## **Atossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa's Microcatheter Technology**

SEATTLE, Oct. 16, 2017 (GLOBE NEWSWIRE) -- **Atossa Genetics** (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that the Ernest Mario School of Pharmacy at Rutgers, The State University at New Jersey, plans to conduct a study utilizing Atossa's intraductal microcatheter technology.

The Rutgers researchers believe that directly administering drugs into the breast duct where breast cancer grows, by inserting microcatheters into the nipple, is a better alternative than systemic administration, because the drugs will be directly delivered to the tissue. The Rutgers program uses a unique directed delivery system comprised of nanoscale pharmaceutical carriers loaded with single drugs. The long-term goal of the research program is to develop a locally administered drug delivery system that selectively targets and delivers pathway-specific targeting therapeutics to eliminate breast cancer cells and cancer stem-like cells while sparing normal breast cells.

"We are encouraged that a leading research institution like Rutgers recognizes the potential merit of our microcatheter technology. Atossa fully supports additional research utilizing our patented microcatheter technology," stated Steven Quay, MD, PhD, Atossa CEO and President.

The Rutgers program is in the research and development phase and has not been approved by the FDA or any other regulatory body. Studies demonstrating safety and efficacy, among other things, and regulatory approvals will be required before commercialization.

### **About Atossa Genetics**

Atossa Genetics Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit [www.atossagenetics.com](http://www.atossagenetics.com).

### **Forward-Looking Statements**

Forward-looking statements in this press release, which Atossa undertakes no obligation

to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.  
Kyle Guse  
CFO and General Counsel  
866 893-4927  
[kyle.guse@atossagenetics.com](mailto:kyle.guse@atossagenetics.com)

Investor Relations Contact

Scott Gordon  
CorProminence LLC  
377 Oak Street  
Concourse 2  
Garden City, NY 11530  
Office: 516.222.2560  
[scottg@corprominence.com](mailto:scottg@corprominence.com)



Source: Atossa Genetics, Inc.